Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $9.4200 (1.51%) ($9.0700 - $9.7800) on Tue. Dec. 10, 2019. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.29% (three month average) | RSI | 64 | Latest Price | $9.4200(1.51%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 4% a day on average for past five trading days. | Weekly Trend | TGTX advances 4.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(65%) ARKG(59%) IBB(58%) ARKK(57%) IWO(57%) | Factors Impacting TGTX price | TGTX will decline at least -2.645% in a week (0% probabilities). VIXM(-40%) VXX(-38%) UUP(-7%) TLT(-7%) IGOV(-1%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -2.645% (StdDev 5.29%) | Hourly BBV | 0 () | Intraday Trend | 2.6% | | | |
|
5 Day Moving Average | $8.34(12.95%) | 10 Day Moving Average | $8.12(16.01%) | 20 Day Moving Average | $7.96(18.34%) | To recent high | 0% | To recent low | 84.7% | Market Cap | $1.193b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |